1. Introduction {#sec1}
===============

Surgery with a curative aim treats not only all the tumor mass but also its subclinical extensions (if clinically there are). This standard method is used in cervical cancer of stage IIA and under \[[@B1], [@B2]\]. Concomitant radiochemotherapy, on the other hand, has been the therapeutic standard for stages IB2 cancers with tumors mass greater than 4 centimeters to stage IVA since the 2000s \[[@B3], [@B4]\]. Accuracy in staging is a prerequisite for a successful curative surgery. The International Federation of Obstetrics and Gynecology (FIGO) is the most widely used staging system \[[@B5], [@B6]\]. However, magnetic resonance imaging (MRI) can help with staging \[[@B7], [@B8]\].

These different methods can cause discrepancies and errors compared to surgical and pathological staging, errors ranging between 17 and 32% for stage IB and between 50 and 64% for the stages IIB and IIIB \[[@B9], [@B10]\].

In our countries where the technical platform is limited, very few scientific studies have focused on the degree of concordance between pre-, intra-, and postoperative staging.

The objective of this study was to evaluate the concordances and discrepancies observed between different staging in a cohort of patients operated on for cervical cancer in Sub-Saharan Africa (Côte d\'Ivoire and Burkina Faso).

2. Patients and Method {#sec2}
======================

This retrospective study was carried out jointly in the Oncology and Gynecology Departments of the University hospital of Treichville and the General Surgery Department of the University Hospital of Yalgado Ouédraogo in Abidjan and Ouagadougou, respectively. We identified 78 patients with histologically confirmed squamous cell carcinoma of the uterine cervix diagnosed between June 1, 2015, and May 31, 2016. The patients were operated on in different health care facilities in these countries. We analyzed the patients\' characteristics, the conditions in which the clinical examination and the staging were done, the surgical reports, and the results of the histopathological examination.

2.1. Initial Clinical Classification {#sec2.1}
------------------------------------

Patients were examined by one or more medical specialists (gynecologists and/or oncologists) or general practitioners, sometimes under general anesthesia (narcosis). Some examinations (endoscopic and morphological imaging) helped to establish the initial classification according to FIGO (cystoscopy, rectoscopy, pelvic MRI, pelvic CT, and pelvic ultrasound).

2.2. Peroperative Staging {#sec2.2}
-------------------------

The surgical indication was only given after preoperative staging. In every case, the indication was for an enlarged total colpohysterectomy with iliopelvic lymphadenectomy. A surgical report was systematically written after surgery. It assessed the characteristics of the tumor, the degree of parietal and regional infiltration, the number of lymph nodes removed, the ratio of lymph nodes removed/infiltrated, and the quality of the surgical resection.

2.3. Postoperative Pathology Staging {#sec2.3}
------------------------------------

All surgical specimens were delivered within 48 hours of surgery to the anatomic pathology laboratories to determine macroscopic characteristics, histological type, number of invaded lymph nodes, resection margins, vascular emboli, and histopathological staging. This staging was done according to the pTNM staging system \[[@B11], [@B12]\] and the pT category allowed defining the FIGO postoperative classification.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Patient and tumor characteristics were described by the mean, median, and proportion. The concordance between the different stages was evaluated using the Cohen kappa coefficient \[[@B13], [@B14]\] and represented in [Table 1](#tab1){ref-type="table"}.

Survival was calculated using Kaplan-Meier\'s method, taking into account the time of participation (in months) and the time between the date of diagnosis and the date of the latest data collected. The follow-up time for patients was 18 months. The latest data were collected from the medical files. For patients who died during hospitalization, the last data recorded were collected from their medical records. Other patients or their relatives were contacted by phone to know their status ("alive" or "deceased"). Survival curves were compared using the Log rank test \[[@B15]\].

The statistical analysis was done using Stata 11 and Epi-Info 3.5.3 software. A threshold of significance of 0.05 was used for analysis.

3. Results {#sec3}
==========

Seventy-eight (78) patients with an average age of 43 years met the inclusion criteria ([Table 2](#tab2){ref-type="table"}).

Concordance was poor for preoperative versus postoperative staging with Cohen kappa coefficient at 18.07% ([Table 3](#tab3){ref-type="table"}). On the other hand, it was good (Cohen kappa Cohen 79%) for intraoperative versus postoperative staging ([Table 5](#tab5){ref-type="table"}).

When studying logistic regression analysis, factors related to discordance were found to be multifactorial. In univaried analysis, pain, metrorrhagia, accidental discovery, number of examiners, type of examiner, examination without narcosis, obesity, and failure to perform a CT scan were the overriding factors.

After adjusting other variables, those significantly related to the discrepancy were the type of examiner, the type of morphological examination, and the absence of examination under narcosis ([Table 4](#tab4){ref-type="table"}).

Regardless of the type of comparison (preoperative versus postoperative, intraoperative versus postoperative), survival at 18 months was significantly greater when there was concordance than when there was not (76.5% versus 27.8%, 48.3% versus 19.8%) (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

In Sub-Saharan Africa in general and in Côte d\'Ivoire in particular, surgery remains the therapeutic method of reference for cervical cancers \[[@B16], [@B17]\].

However, this method, in our study for the most part, does not obey the laws of a curative surgery. Indeed, the poor preoperative/intraoperative staging concordance indicates the understaging of our patients. These discrepancies observed in staging could be explained by several factors. They are the inadequacies or the lack of skilled personnel dealing with cervical cancers, the general absence of diagnosis and therapeutic strategy decided during a multidisciplinary team meeting, and, finally, the absence of complete workup to assess the resectability criteria and the operability of the cancer. These various characteristics, which have also been demonstrated in other African series \[[@B18], [@B19]\], are responsible for frequent postoperative progression with chronic obstructive kidney disease by ureter encasement \[[@B18]\]. Very little data is available in western series due to the paucity of cervical cancers \[[@B20]\]. Moreover, in medicalized countries, the surgical indication is the consequence of an exhaustive pretherapeutic assessment and therefore of care that is similar to the evolutionary stage \[[@B21]\]. However, some western studies have also shown discrepancies ranging from 15 to 20% \[[@B9], [@B10]\]. The low overall survival rate observed (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) is the consequence of these different discrepancies making cervical cancer of bad prognosis \[[@B22]\]. The poor prognosis is related to an inappropriate indication for surgery and thus leading to tumor residue and usually R2 resections.

5. Conclusion {#sec5}
=============

For most of our patients, cervical cancer surgery does not meet the criteria of an excision. The various parameters within the framework of the pretherapeutic assessment were insufficiently realized and resulted in a discrepancy between pre-, intra-, and postoperative staging. The stages in which the majority of our patients were consulted were amenable to concomitant radiochemotherapy. The different survival rates were poor, indicating the somber outcome of cervical cancer for most of our patients. This study advocates for efficient management of cervical cancer, which is a model for prevention and healing. Indeed, its risk factors are well known, its natural history is known, and it is curable when detected early.
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  Kappa coefficient   Level of concordance
  ------------------- ----------------------
  \>0,81              Very good
  0,80--0,61          Good
  0,60--0,41          Moderate
  0,40--0,21          Mediocre
  0,20--0,00          Poor
  \<0,001             Very poor

###### 

Patients and examination conditions characteristics.

  Parameters                     Number   Percentage (%)
  ------------------------------ -------- ----------------
  *Obesity*                                
   (i) Yes                       32       41,03
   (ii) No                       46       58,97
  *Circumstance of discovery*              
   (i) Pain                      51       65,38
   (ii) Metrorrhagia             50       64,10
   (iii) Leucorrhea              42       53,85
   (iv) Screening                60       76,92
  *Performance status*                     
   (i) 1                         50       64,10
   (ii) 2                        28       36,90
  *Nombre of examiners*                    
   (i) 1                         21       26,92
   (ii) 2                        31       39,74
   (iii) 3                       26       33,33
  *Type of examiner*                       
   (i) Specialist                45       42,31
   (ii) Generalist               33       57,69
  *Examination under narcosis*             
   (i) Yes                       40       51,28
   (ii) No                       38       48,72
  *Patient cooperation*                    
   (i) Yes                       60       76,92
   (ii) No                       10       23,08
  *Pelvic ultrasound*                      
   (i) Yes                       59       75,64
   (ii) No                       19       24,36
  *Pelvic CT scan*                         
   (i) Yes                       38       48,72
   (ii) No                       40       51,28
  *MRI*                                    
   (i) Yes                       19       24,36
   (ii) No                       59       75,64

###### 

Clinical staging versus intraoperative staging.

  Preoperative staging   Intraoperative staging   Level of underestimation                                            
  ---------------------- ------------------------ -------------------------- -------- ------- ------- ------- ------- -----------
  IA                     **1**                    0                          0        0       0       0       0       0,0%
  IB                     0                        **10**                     4        2       1       0       0       41,2%
  IIA                    0                        0                          **10**   5       4       12      3       70,6%
  IIB                    0                        0                          1        **2**   2       7       8       85,0%
  IIIA                   0                        0                          0        0       **0**   0       1       100%
  IIIB                   0                        0                          0        0       0       **1**   2       66,6%
  IVA                    0                        0                          0        0       0       1       **1**   **50,0%**

###### 

Factors related to the clinical versus intraoperative staging discrepancies (logistic regression).

                               Univariate analysis   Multivariate analysis                                              
  ---------------------------- --------------------- ----------------------- ------------------ ------ ---------------- ------------
  Pain                                                                                                                   
   No                          1                                                                1                        
   Yes                         12,57                 \[4,1--38,9\]           \<**10**^−**4**^   4,1    0,6--26,6        NS
  Metrorrhagia                                                                                                           
   No                          1                                                                1                        
   Yes                         11,06                 \[3,6--33,6\]           \<**10**^−**4**^   1,1    0,09--13,1       NS
  Screening                                                                                                              
   No                          1                                                                1                        
   Yes                         45,3                  \[8,9--231,8\]                             30,5   \[4,5--207,2\]   **0,0005**
  Number of examiners                                                                                                    
   1                           1                                                                1                        
   2                           0,2                   \[0,02--1,9\]           0,16               0,19   0,02--2,4        NS
   3                           0,02                  \[0,002--0,2\]          \<**10**^−**3**^   0,14   0,007--2,9       NS
  Type of examiner                                                                                                       
   Specialist                  1                                                                1                        
   Generalist                  9,6                   \[2,5--35,9\]                              1,4    0,2--11,8        NS
  Examination under narcosis                                                                                             
   No                          14,3                  \[3,8--54,1\]           **10** ^−**4**^    6,5    \[1,3--31,7\]    **0,02**
   Yes                         1                                                                1                        
  Obesity                                                                                                                
   No                          1                                                                1                        
   Yes                         25,9                  \[2,4--33,2\]           **10** ^−**3**^    6,9    \[1,2--40,9\]    **0,03**
  CT scan                                                                                                                
   No                          6,6                   \[2,1--20,4\]           **10** ^−**3**^    0,3    0,05--1,5        NS
   Yes                         1                                                                1                        

###### 

Table of concordance between intraoperative staging and postoperative staging.

  Intraoperative staging   Postoperative staging                                                                      
  ------------------------ ----------------------- ------- -------- -------- ------- ------- -------- ------- ------- ---
  Ia                       **1**                   0       0        0        0       0       0        0       0       0
  Ib1                      0                       **0**   0        0        0       0       0        0       0       0
  Ib2                      0                       0       **10**   0        0       0       0        0       0       0
  IIa                      0                       0       0        **14**   0       0       0        1       0       0
  IIb                      0                       0       0        0        **8**   0       1        0       0       0
  IIIa                     0                       0       0        0        0       **7**   0        0       0       0
  IIIb                     0                       0       0        0        0       2       **18**   0       0       1
  IVa                      0                       0       0        0        0       0       0        **6**   0       9
  IVb                      0                       0       0        0        0       0       0        0       **0**   0

*∗* refers to the pathology classifications (pT4) without any "a" or "b" specifications.
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